Cangene shares defence costs for Nucleic Acid Sequence Based Amplification (NASBA):
This article was originally published in Clinica
Canadian pharmaceutical company Cangene has agreed to escrow Can$1 million as its share of the defence costs of a threatened legal action by Roche against Akzo. The action has been brought against Akzo's HIV kits which utilise Cangene's NASBA technology (see Clinica No 674, p 13). "This resolution recognises that while Roche filed against Akzo after they had signed the NASBA sale agreement, Cangene has some obligation to assist Akzo in dealing with it," says Cangene's CEO James Rae.
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 10 December.
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.